Novartis May Be Looking to Buy Amneal Generics

Nov 14, 2016

Bloomberg

Novartis is discussing the possible acquisition of U.S. generic-drugs maker Amneal Pharmaceuticals, in a bid to boost its Sandoz generics business, says Bloomberg sources.

Sources told Bloomberg that the sale could value NJ-based Amneal at as much as $8 billion. Amneal has 115 approved molecules; among them the antiviral acyclovir to treat herpes, as well as gabapentin for epilepsy and pain.

Novartis' investment in biosimilars is beginning to pay off, with its portfolio of four drugs expected to cross the $1 billion sales threshold in 2016.

Read the Bloomberg coverage

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments